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Dopa-responsive dystonia (DRD) is a form of torsion dystonia 
first described by the Japanese neurologist Segawa in 1971 
as progressive hereditary dystonia with prominent diurnal 
fluctuations [1].  
In most patients, the disease starts in one leg in the first 
decade of life and spreads to other limbs by the time the patient 
enters their late 20s [2]. Gait disturbance is typically the earliest 
manifestation of DRD often mistakenly interpreted as cerebral 
palsy [3]. In the early stages of the disease, the symptoms 
are absent in the morning but worsen towards evening; such 
aggravation depends more on the number of waking hours 
than on physical activity itself. As the disease progresses, the 
patient starts to experience morning symptoms as well [4].
There are 2 types of dystonia: classic postural dystonia, 
e.g. postural instability due to increased muscle tone, and 
phasic dystonia, which is a combination of postural instability 
and phasic dystonic movements. There are single reports of 
isolated hand tremor, permanent foot deformities (clubfoot) and 
dystonia of individual muscles [5].
A trial of levodopa is the main diagnostic test in patients 
with suspected DRD. A good, sustained response to this drug 
indicates a high probability of DRD.
The recommended starting dose of levodopa is 1 mg/kg
per day. It should be gradually increased until sustained 
improvement is achieved or side effects are reported by the 
patient. The majority of patients improve at 4–5 mg/kg per day. 
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ДОФА-зависимая дистония (ДЗД) — это редкое прогрессирующее генетически гетерогенное заболевание с манифестированием в детском возрасте, 
в три раза чаще встречающееся у женщин. В статье описан клинический случай синдрома Сегавы у молодой женщины с нижним парапарезом, 
дистонией стоп (больше справа), нарушением функции ходьбы, поступившей в неотложном порядке в неврологическое отделение с жалобами на 
выраженное ограничение ходьбы и самообслуживания. В результате дообследования, включающего в себя тест с Леводопой и прямое автоматическое 
секвенирование по Сенгеру, у пациентки была диагностирована ДЗД. Проведено лечение Леводопой, в ходе которого у пациентки регрессировали 
клинические симптомы дистонии. В статье представлены особенности течения заболевания и дифференциальной диагностики, а также генетическая 
детерминированность и тактика лечения.  
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A CASE REPORT OF DOPA-RESPONSIVE DYSTONIA IN A YOUNG WOMAN 
Dopa-responsive dystonia (DRD) is a rare progressive genetically heterogenous disorder with pediatric onset. DRD is 3 times as prevalent in women than in men. 
This article reports a clinical case of DRD in a young female presenting with paraparesis, foot dystonia (more pronounced in the right foot) and pronounced walking 
impairment, who was admitted for emergency treatment to a Neurology Unit. Based on the additional tests, which included a levodopa trial and Sanger sequencing, 
the patient was diagnosed with DRD. Levodopa caused a considerable improvement of the symptoms. The article describes the clinical features of the disease, 
talks about its differential diagnosis, genetic predisposition and treatment strategy.
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Fig. 1. Dystonia of the right foot before therapy with levodopa Fig. 2. Brain MRI: grade I cortical atrophy, no signs of focal or diffuse cerebral pathology 
In the absence of a positive response to levodopa, the drug 
should discontinue no sooner than 3 months after the onset 
of therapy [6].
To differentiate between DRD and other conditions alleviated 
by levodopa, pterins are measured in the cerebrospinal fluid 
of the patient (CSF). The positive levodopa trial and elevated 
CSF pterins are strongly suggestive of DRD [7]. The diagnosis 
can be confirmed by means of molecular genetic testing for 
mutations in the GCH1 gene [8].
Clinical case
A female patient underwent a series of medical examinations 
and received treatment for DRD at the Neurology Unit of the 
Central Clinical Hospital № 23 (Yekaterinburg) in 2015–2017. 
The diagnosis was based on the presence of the heterozygous 
nucleotide sequence variant с.248g>a (p.Gly83Asp) detected 
using PCR . 
The patient was born in 1982. Her family members first 
became aware of her symptoms when she was 12 years old. 
The symptoms included weakness in the legs, gate disturbance, 
muscle fatigue in the legs exacerbated on walking, a feeling 
of knee rotation, toe curling while walking, and psychological 
tension. According to the patient, she also felt occasional 
weakness in her arms. The patient’s parents sought medical 
advice with a neurologist. Provisional diagnoses included 
Strümpell–Lorrain disease, paraparesis and paraplegia. The 
patient was prescribed Baclofen, Neuromultivit, Sirdalud 
(tizanidine), paraffin wax therapy, massage, and exercise, to no 
avail. Her condition continued to deteriorate. The patient started 
feeling very weak, lost control over her legs, discontinued 
Baclofen and Sirdalud without consulting the neurologist 
and stopped attending PE classes at school after failing her 
normative assessment tests (especially, the jumping portion). 
Family history. As a child, the patient was raised in a two-
parent family and did not have any developmental delays. At 
the age of 3 years, the patient had chickenpox. After graduating 
from high school, she went on to earn a degree in economy but 
was out of work at the time of this study. The patient denied 
any unhealthy habits. In 2010 she delivered a child by Cesarian 
section. The patient had no past history of serious infections or 
allergies. Due to her condition, she was found disabled in 1995 
and qualified for category 2 of disability in 2000. 
In 2015, she was referred for botulinum toxin therapy, but 
never received it for reasons unknown. At about that time, her 
symptoms started to aggravate: she experienced pronounced 
difficulty walking and could no longer take care of herself. 
Eventually, she was admitted to the Neurology Unit for further 
tests. 
On admission, her condition was moderately severe, the skin 
appeared pale and dry. The pulse was regular, 72 beats per min; 
BP was 130/75, and respiration rate was 16 breaths per min. 
On a neurological examination, the patient was fully conscious 
and oriented; speech was scaning. Her cranial nerves were 
unremarkable. Muscle strength was reduced in the distal legs 
(the patient scored 3.5 points); muscle tone was increased on 
the right side (extrapyramidal signs) (Fig. 1); tonic spasms were 
observed in the lower limbs. Upper limb reflexes were moderate 
and symmetric; in the lower limbs, reflexes were diminished. 
No pathologic reflexes were observed. In coordination tests the 
patient was uncertain; a positive Romberg was present. The 
patient showed no signs of meningeal irritation. The range of 
motion was limited in all spinal cord segments. The preliminary 
diagnosis based on the patient’s complaints, medical history 
and clinical presentations was consistent with encephalo-
polyradiculoneuropathy, paraparesis, feet dystonia (more 
pronounced on the right side) and walking impairment. Results 
of laboratory tests, including complete blood count, urinalysis 
and blood biochemistry test, were within the normal reference 
range. On ECG, the sinus rhythm was 73 beats per minute. 
Electromyoneurography of the lower and upper limbs revealed 
mild radiculopathy of L4–L5, S1, C7–C8, and Th1, moderate 
ulnar neuropathy at the elbow and mild axonal neuropathy of 
the right tibial and peroneal nerves. MRI of the brain revealed 
grade 1 cortical atrophy. Nothing was suggestive of a focal 
or diffuse cerebral pathology (Fig. 2) An earlier cervical spine 
MRI scan performed in 2007 had been suggestive of stage 1 
degenerative disc disease at С3–С6 and a small disc osteophyte 
complex at С5–С6, with no pathologic foci in the spinal cord 
(Fig. 3). DNA testing for GCHI mutations was conducted on 
March 13, 2017: the coding sequence and the adjacent introns 
of the GCHI gene responsible for torsion dystonia (DYT5) were 
analyzed using Sanger sequencing. The heterozygous variant 
с.248g>a (p.Gly83Asp) was detected. Thus, torsion dystonia 
was confirmed by molecular genetic testing. 
Based on the data from a follow-up MRI scan, the diagnosis 
was revised and corrected to G24.8 Dopa-responsive dystonia 
involving both feet, walking impairment; polyradiculoneuropathy 
in the presence of degenerative disc disease of the cervical and 
lumbosacral spine; pain syndrome; motor impairment. 
The patient was prescribed regular daily exercise, a 
dopamine mimetic drug, a vasodilator, a hepatoprotective 
agent, vitamins, and a cholinesterase inhibitor. She was 
followed up by her local healthcare provider. The patient started 
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Fig. 3. Cervical spine MRI: stage 1 degenerative disc disease at С3–С6, small disc 
osteophyte complex at С5–С6. No pathological foci detected
taking the dopamine mimetic drug after the definitive diagnosis 
was made and continued through pregnancy. When she got 
pregnant, she reduced the dosage by 50%, with no loss of 
effect.
Discussion
Patients with DRD can have 4 different mutations in the 
gene involved in the synthesis of guanosine triphosphate 
cyclohydrolase-I (GCH1) [9]. This enzyme participates in the 
synthesis of tetrahydrobiopterin (ВН4), the tyrosine hydroxylase 
(TG) cofactor that converts L-tyrosine into L-DOPA, which leads 
to a reduction in dopamine concentrations in the striatum. 
Patients with the autosomal-dominant type of inheritance carry 
this mutant gene on chromosome 14 (14qll-q24.3). Patients 
with autosomal-recessive inheritance carry this gene on 
chromosome 11p15.5 of the TG gene [10].   
The prevalence of the neurometabolic disease is 0.5-1 
cases per 1 million population [11]; it is probably underreported 
because some patients present with very mild symptoms. 
Manifestation of symptoms at the age of 4–8 years is 
accompanied by parkinsonian features and muscle dystonia 
resulting in gait disturbance. Because of increased muscle 
tone in the legs and signs of damage to the pyramidal tracts, 
the condition can be mistakenly interpreted as cerebral palsy 
or inherited spastic paraplegia [12]. Over time, dystonia of the 
lower limbs progresses to generalized dystonia. The disease is 
characterized by diurnal fluctuations of motor symptoms, which 
improve in the morning after sleep and aggravate towards 
evening. Evaluation of the therapeutic effect of levodopa is a 
good diagnostic technique in patients whose dystonia is not 
associated with hypoxic-ischemic encephalopathy [13].  
In the described clinical case, the patient had reduced 
muscle strength in the distal leg (3.5 points), increased muscle 
tone on the right side (extrapyramidal signs) gait disturbance 
with dystonic movements of the lower libs, diminished reflexes 
in the lower limbs and a positive Romberg.
Given that the patient’s symptoms regressed after the 
combination therapy with levodopa and carbidopa, the 
definitive diagnosis was DRD. At present, the patient is free of 
dystonia symptoms. 
CONCLUSION
Dopa-responsive dystonia is a rare genetic pediatric-onset 
disease. Due to diagnostic difficulties, the definitive diagnosis can 
be delayed. In the early stages of the disease, gait disturbance 
may be overlooked by the parents. An accurate medical history 
and a thorough neurological examination focused on detecting 
the presence of diurnal fluctuations and evaluating the patient’s 
response to medication therapy are instrumental in establishing 
the accurate diagnosis. The clinical case described in this article 
might remind healthcare practitioners to stay vigilant about this 
pathology when examining a patient.
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